Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FEC followed by weekly paclitaxel plus trastuzumab in stage II-III HER2-positive breast cancer
2010-021600-24Phase 2Terminated
- Sponsor
- Innovative Sensor Technology IST AG
- Start
- Nov 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, paclitaxel, fluorouracil, epirubicin and cyclophosphamide in breast cancer, sponsored by Innovative Sensor Technology IST AG. Primary endpoint: Pathological complete response. Started Nov 2010; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-021600-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021600-24.